Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Abstract

Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved the outcomes of patients with many types of cancer, although only 20-40% of patients derive benefit from these new therapies. PD-L1, quantified using immunohistochemistry assays, is currently the most widely validated, used and accepted biomarker to guide the selection of patients to receive anti-PD-1 or anti-PD-L1 antibodies. However, many challenges remain in the clinical use of these assays, including the necessity of using different companion diagnostic assays for specific agents, high levels of inter-assay variability in terms of both performance and cut-off points, and a lack of prospective comparisons of how PD-L1 + disease diagnosed using each assay relates to clinical outcomes. In this Review, we describe the current role of PD-L1 immunohistochemistry assays used to inform the selection of patients to receive anti-PD-1 or anti-PD-L1 antibodies, we discuss the various technical and clinical challenges associated with these assays, including regulatory issues, and we provide some perspective on how to optimize PD-L1 as a selection biomarker for the future treatment of patients with solid tumours.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-021-00473-5

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 198 references

Research works printed but not linked: 1

  1. Travis, W. D. et al. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart (IARC Press, 2015).

Cited by

See all 1,575

Metadata

Authors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R.
Affiliations
  • Tisch Cancer Institute (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Brigham and Women's Hospital (US)
  • University of Aberdeen (GB)
  • The University of Texas MD Anderson Cancer Center (US)
  • Yale University (US)
  • Princess Margaret Cancer Centre (CA)
Corresponding author
Hirsch, Fred R.
Venue
Nature Reviews Clinical Oncology
Published
2021-02-12
Volume
18
Issue
6
Pages
345-362
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W3128131226
Cited by
1,575
References
198
Citations by year
2026: 221 · 2025: 355 · 2024: 351 · 2023: 312 · 2022: 261 · 2021: 72
FWCI
30.26
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-L1, immune checkpoint inhibitors, predictive biomarkers, anti-PD-1, PD-L1 inhibitors, companion diagnostics, cut-off values, patient selection, solid tumors, regulatory challenges, tumor immunogenicity
MeSH terms
Immune Checkpoint Inhibitors, Biopsy, Humans, Immunohistochemistry, Neoplasms, Specimen Handling, Biomarkers, Tumor, Treatment Outcome, Biomarkers, Pharmacological, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 as a biomarker of response to immune-checkpoint inhibitors. https://app.cochat.ai/papers/10.1038/s41571-021-00473-5
The paper
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00473-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.